234 related articles for article (PubMed ID: 15492249)
1. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
2. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins.
Lasorella A; Noseda M; Beyna M; Yokota Y; Iavarone A
Nature; 2000 Oct; 407(6804):592-8. PubMed ID: 11034201
[TBL] [Abstract][Full Text] [Related]
3. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
4. Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL
Oncogene; 2005 Sep; 24(41):6231-40. PubMed ID: 15940251
[TBL] [Abstract][Full Text] [Related]
5. The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Cancer; 2008 Feb; 112(3):552-61. PubMed ID: 18085637
[TBL] [Abstract][Full Text] [Related]
6. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
7. Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma.
Lasorella A; Boldrini R; Dominici C; Donfrancesco A; Yokota Y; Inserra A; Iavarone A
Cancer Res; 2002 Jan; 62(1):301-6. PubMed ID: 11782392
[TBL] [Abstract][Full Text] [Related]
8. Id2 drives differentiation and suppresses tumor formation in the intestinal epithelium.
Russell RG; Lasorella A; Dettin LE; Iavarone A
Cancer Res; 2004 Oct; 64(20):7220-5. PubMed ID: 15492237
[TBL] [Abstract][Full Text] [Related]
9. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Id2 expression by CCAAT/enhancer binding protein beta.
Karaya K; Mori S; Kimoto H; Shima Y; Tsuji Y; Kurooka H; Akira S; Yokota Y
Nucleic Acids Res; 2005; 33(6):1924-34. PubMed ID: 15809228
[TBL] [Abstract][Full Text] [Related]
11. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
12. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
13. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
14. [Id2, a go-between in the Myc-Rb pair].
Bénard J; Raguenez G; Douc-Rasy S
Bull Cancer; 2000 Dec; 87(12):877-80. PubMed ID: 11174116
[No Abstract] [Full Text] [Related]
15. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
16. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors.
Schuldiner O; Benvenisty N
Oncogene; 2001 Aug; 20(36):4984-94. PubMed ID: 11526483
[TBL] [Abstract][Full Text] [Related]
17. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.
Cardone M; Kandilci A; Carella C; Nilsson JA; Brennan JA; Sirma S; Ozbek U; Boyd K; Cleveland JL; Grosveld GC
Mol Cell Biol; 2005 Mar; 25(6):2395-405. PubMed ID: 15743832
[TBL] [Abstract][Full Text] [Related]
18. Id2 haploinsufficiency in mice leads to congenital hydronephrosis resembling that in humans.
Aoki Y; Mori S; Kitajima K; Yokoyama O; Kanamaru H; Okada K; Yokota Y
Genes Cells; 2004 Dec; 9(12):1287-96. PubMed ID: 15569159
[TBL] [Abstract][Full Text] [Related]
19. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
20. Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EmuMyc transgenic mice.
Mikkers H; Allen J; Berns A
Oncogene; 2002 Sep; 21(43):6559-66. PubMed ID: 12242653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
